HRP20110485T1 - Pirolopirazoli kao potentni inhibitori kinaza - Google Patents

Pirolopirazoli kao potentni inhibitori kinaza Download PDF

Info

Publication number
HRP20110485T1
HRP20110485T1 HR20110485T HRP20110485T HRP20110485T1 HR P20110485 T1 HRP20110485 T1 HR P20110485T1 HR 20110485 T HR20110485 T HR 20110485T HR P20110485 T HRP20110485 T HR P20110485T HR P20110485 T1 HRP20110485 T1 HR P20110485T1
Authority
HR
Croatia
Prior art keywords
alkylene
compound according
image
alkyl
membered
Prior art date
Application number
HR20110485T
Other languages
English (en)
Croatian (hr)
Inventor
Bouzida Djamal
Dong Liming
Guo Chuangxing
Hong Yufeng
Li Haitao
T. Marakovits Joseph
Yang Anle
Zhang Junhu
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HRP20110485T1 publication Critical patent/HRP20110485T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HR20110485T 2005-01-10 2011-06-30 Pirolopirazoli kao potentni inhibitori kinaza HRP20110485T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64290005P 2005-01-10 2005-01-10
US73377005P 2005-11-04 2005-11-04
PCT/IB2005/003975 WO2006072831A1 (fr) 2005-01-10 2005-12-28 Pyrrolopyrazoles, puissants inhibiteurs de kinases

Publications (1)

Publication Number Publication Date
HRP20110485T1 true HRP20110485T1 (hr) 2011-07-31

Family

ID=36463340

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110485T HRP20110485T1 (hr) 2005-01-10 2011-06-30 Pirolopirazoli kao potentni inhibitori kinaza

Country Status (30)

Country Link
US (2) US8067591B2 (fr)
EP (1) EP1838718B1 (fr)
JP (1) JP4250195B2 (fr)
KR (1) KR100919343B1 (fr)
CN (1) CN101115760B (fr)
AP (1) AP2007004061A0 (fr)
AT (1) ATE512972T1 (fr)
AU (1) AU2005323797B2 (fr)
BR (1) BRPI0518509A2 (fr)
CA (1) CA2593428C (fr)
CU (1) CU23778B7 (fr)
CY (1) CY1111752T1 (fr)
DK (1) DK1838718T3 (fr)
EA (1) EA011815B1 (fr)
ES (1) ES2365245T3 (fr)
GE (1) GEP20094785B (fr)
HK (1) HK1114380A1 (fr)
HR (1) HRP20110485T1 (fr)
IL (1) IL184275A0 (fr)
MA (1) MA29141B1 (fr)
MX (1) MX2007008385A (fr)
NO (1) NO20073859L (fr)
NZ (1) NZ556273A (fr)
PL (1) PL1838718T3 (fr)
PT (1) PT1838718E (fr)
RS (1) RS51891B (fr)
SI (1) SI1838718T1 (fr)
TN (1) TNSN07254A1 (fr)
WO (1) WO2006072831A1 (fr)
ZA (1) ZA200705628B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1979356T3 (da) 2005-12-21 2013-11-18 Pfizer Prod Inc Carbonylaminopyrrolopyrazoler, kraftige kinaseinhibitorer
NZ578876A (en) 2007-02-07 2012-12-21 Pfizer 3-amino-pyrrolo[3,4-c]pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors
UA96618C2 (en) * 2007-02-07 2011-11-25 Пфайзер Инк. 3-amino-pyrrolo[3,4-c] pyrazole- 5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors
CN104356136A (zh) * 2007-04-12 2015-02-18 辉瑞大药厂 作为蛋白酶c抑制剂的3-酰氨基-吡咯并[3,4-c]吡唑-5(1h,4h,6h)甲醛衍生物
CN101808693A (zh) 2007-07-25 2010-08-18 百时美施贵宝公司 三嗪激酶抑制剂
FR2928150A1 (fr) 2008-02-29 2009-09-04 Vetoquinol Sa Sa Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens
JPWO2009130900A1 (ja) * 2008-04-24 2011-08-11 日本曹達株式会社 オキシム誘導体、中間体化合物および植物病害防除剤
EP2145891A1 (fr) 2008-07-09 2010-01-20 Vetoquinol S.A. Dérivés de 9-substitués-5-carboxy-oxadiazino-quinolone, leur préparation et leur application en tant qu'antibactériens
WO2011044264A2 (fr) * 2009-10-06 2011-04-14 Afraxis, Inc. Pyrrolopyrazoles pour le traitement de troubles du snc
KR101483215B1 (ko) * 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
CN103298461A (zh) 2010-11-17 2013-09-11 霍夫曼-拉罗奇有限公司 治疗肿瘤的方法
EP2734530A1 (fr) 2011-07-19 2014-05-28 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
WO2013113781A1 (fr) 2012-02-03 2013-08-08 Basf Se Composés de pyrimidine fongicides i
WO2013113776A1 (fr) 2012-02-03 2013-08-08 Basf Se Composés de pyrimidine fongicides
WO2013113791A1 (fr) 2012-02-03 2013-08-08 Basf Se Composés de pyrimidine fongicides
JP2015508752A (ja) 2012-02-03 2015-03-23 ビーエーエスエフ ソシエタス・ヨーロピアBasf Se 殺菌性ピリミジン化合物
WO2013113782A1 (fr) 2012-02-03 2013-08-08 Basf Se Composés de pyrimidine fongicides
WO2013113720A1 (fr) 2012-02-03 2013-08-08 Basf Se Composés de pyrimidine fongicides
BR112014018909A8 (pt) 2012-02-03 2017-07-11 Basf Se Compostos, processo para a preparação dos compostos, composição agroquímica, método para o combate dos fungos, utilização dos compostos e semente
WO2013113716A1 (fr) 2012-02-03 2013-08-08 Basf Se Composés de pyrimidine fongicides
WO2013113778A1 (fr) 2012-02-03 2013-08-08 Basf Se Composés de pyrimidine fongicides
WO2013113773A1 (fr) 2012-02-03 2013-08-08 Basf Se Composés fongicides de pyrimidine
WO2013113719A1 (fr) 2012-02-03 2013-08-08 Basf Se Composés de pyrimidine fongicides ii
CN104220435A (zh) 2012-03-13 2014-12-17 巴斯夫欧洲公司 杀真菌的嘧啶化合物
WO2013135672A1 (fr) 2012-03-13 2013-09-19 Basf Se Composés de pyrimidine fongicides
MX2014010953A (es) * 2012-03-16 2014-10-13 Hoffmann La Roche Metodos para tratamiento de melanoma con inhibidores pak1.
JP6186440B2 (ja) 2012-09-19 2017-08-23 ノバルティス アーゲー キナーゼ阻害剤としてのジヒドロピロリジノピリミジン
ES2615743T3 (es) * 2012-10-15 2017-06-08 Pfizer Ireland Pharmaceuticals Procedimiento de preparación de voriconazol y análogos de los mismos
EP3046915A1 (fr) 2013-09-16 2016-07-27 Basf Se Composés pyrimidines fongicides
WO2015036059A1 (fr) 2013-09-16 2015-03-19 Basf Se Composés fongicides de pyrimidine
AU2016281225B2 (en) 2015-06-15 2020-10-15 Ube Corporation Substituted dihydropyrrolopyrazole derivative
CN104926735A (zh) * 2015-06-16 2015-09-23 上海合全药物研发有限公司 4-氯-5-氟-2-甲基嘧啶的工业化制备方法
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
WO2017144546A1 (fr) 2016-02-23 2017-08-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement d'un carcinome de rhinopharyngite
AU2017363307B2 (en) 2016-11-22 2021-07-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof
AU2018288841B2 (en) 2017-06-21 2022-09-29 SHY Therapeutics LLC Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease
CA3097543A1 (fr) * 2018-04-16 2019-10-24 The Regents Of The University Of California Inhibiteurs de pak4 et procedes d'utilisation
EP3956446A1 (fr) 2019-04-17 2022-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions de traitement de troubles dépendants de il-1beta mediés par inflamasome nlrp3
WO2021198511A1 (fr) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pour le traitement d'une infection par sars-cov-2
CN111454278B (zh) * 2020-05-15 2021-03-19 四川大学 Pak1抑制剂及其合成和在制备抗肿瘤药物中的应用
WO2022008597A1 (fr) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et composition pharmaceutique pour le traitement de maladies infectieuses
CA3203896A1 (fr) * 2020-12-31 2022-07-07 Anle Yang Inhibiteur de plasmine, son procede de preparation et son application

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3423414A (en) 1966-01-13 1969-01-21 Ciba Geigy Corp Pyrazolopyridines
US3526633A (en) 1968-03-06 1970-09-01 American Cyanamid Co Substituted 2,4,5,6-tetrahydropyrrolo(3,4-c)pyrazoles
US3947467A (en) 1973-08-02 1976-03-30 Eli Lilly And Company 3-(5-Nitro-2-imidazolyl) pyrazoles
JPS5163193A (ja) 1974-11-26 1976-06-01 Yoshitomi Pharmaceutical Tetorahidoropirazoropirijinkagobutsuno seizoho
US6013500A (en) 1998-05-21 2000-01-11 The Trustees Of Columbia University In The City Of New York PAK4, a novel gene encoding a serine/threonine kinase
CN102060857A (zh) 2000-08-10 2011-05-18 辉瑞意大利有限公司 具有激酶抑制剂活性的二环吡唑类、其制备方法和包含它们的药物组合物
CA2493637A1 (fr) * 2002-07-25 2004-02-12 Manuela Villa Bicyclo-pyrazoles actifs inhibiteurs de kinase, procede de preparation et compositions pharmaceutiques contenant ceux-ci
UA81790C2 (uk) 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
US7141568B2 (en) 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
EA200701257A1 (ru) 2007-12-28
AU2005323797B2 (en) 2009-07-09
US20100222342A1 (en) 2010-09-02
US20120264751A1 (en) 2012-10-18
CU20070160A7 (es) 2009-03-16
PT1838718E (pt) 2011-08-17
HK1114380A1 (en) 2008-10-31
PL1838718T3 (pl) 2011-10-31
ATE512972T1 (de) 2011-07-15
ES2365245T3 (es) 2011-09-27
CY1111752T1 (el) 2015-10-07
NO20073859L (no) 2007-10-03
TNSN07254A1 (en) 2008-12-31
RS51891B (en) 2012-02-29
EA011815B1 (ru) 2009-06-30
ZA200705628B (en) 2008-11-26
EP1838718A1 (fr) 2007-10-03
MX2007008385A (es) 2007-08-21
DK1838718T3 (da) 2011-07-25
CA2593428C (fr) 2012-04-17
CA2593428A1 (fr) 2006-07-13
CU23778B7 (es) 2012-02-15
AP2007004061A0 (en) 2007-08-31
IL184275A0 (en) 2007-10-31
KR20070096007A (ko) 2007-10-01
WO2006072831A1 (fr) 2006-07-13
GEP20094785B (en) 2009-09-25
KR100919343B1 (ko) 2009-09-25
JP2008526826A (ja) 2008-07-24
US8530652B2 (en) 2013-09-10
BRPI0518509A2 (pt) 2008-11-25
EP1838718B1 (fr) 2011-06-15
US8067591B2 (en) 2011-11-29
CN101115760B (zh) 2010-11-03
CN101115760A (zh) 2008-01-30
SI1838718T1 (sl) 2011-08-31
MA29141B1 (fr) 2008-01-02
AU2005323797A1 (en) 2006-07-13
NZ556273A (en) 2010-01-29
JP4250195B2 (ja) 2009-04-08

Similar Documents

Publication Publication Date Title
HRP20110485T1 (hr) Pirolopirazoli kao potentni inhibitori kinaza
JP2014507421A5 (fr)
JP2012512891A5 (fr)
CO2022011429A2 (es) Derivados de arilamida con actividad antitumoral
RU2014115847A (ru) Пирролопиримидиновые соединения для лечения злокачественной опухоли
PT1613315E (pt) Derivados da quinolina-2-ona para o tratamento de doenças das vias aéreas respiratórias
RS20080002A (en) N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
JP2008533191A5 (fr)
JP7304128B2 (ja) 白金耐性の克服における使用のためのテキサフィリン-白金(iv)コンジュゲート及び組成物
HRP20030436B1 (en) Ortho-substituted and meta-substituted bis-aryl compounds, method for the production thereof, their use as a medicament, and pharmaceutical preparations containing these compounds
RU2000127751A (ru) Противоопухолевое средство
IL131515A0 (en) Substituted 4-arylmethylene-2-imino-2,3- dihydrothiazoles and derivatives and their pharmaceutical use
JP2008508287A5 (fr)
WO2006040569A8 (fr) Composes d'amide thiophenique destines a etre utilises dans le traitement ou la prophylaxie du cancer
RU2006114045A (ru) Фенил-пиперазиновые производные в качестве модуляторов мускариновых рецепторов
HRP20160044T1 (hr) Novi spojevi fenilamino izonikotinamida
JP2020506895A5 (fr)
CA2406080A1 (fr) Derives antitumoraux d'ecteinascidines
AU2005286833B2 (en) Sulfonyl hydrazines as hypoxia-selective antineoplastic agents
WO2006028977A3 (fr) Composes chiraux spiraniques et leur utilisation dans des reactions catalytiques asymetriques
US20170120231A1 (en) Complexes
JP2015522551A5 (fr)
CA2428019A1 (fr) Modulateurs de recepteurs d'oestrogenes
JP2014521609A5 (fr)
JP2016514160A5 (fr)